지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
등록된 정보가 없습니다.
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression
Clinical and Molecular Hepatology
2024 .04
Anti cancer effect of ursolic acid in melanoma
한국실험동물학회 학술발표대회 논문집
2019 .01
Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences
Clinical and Molecular Hepatology
2024 .04
Protective Effects of Ursolic Acid on Osteoblastic Differentiation via Activation of IER3/Nrf2
치위생과학회지
2019 .01
Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study
Clinical and Molecular Hepatology
2024 .07
Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia
Clinical and Molecular Hepatology
2024 .07
Effects of Metabolic Dysfunction-Associated Steatotic Liver Disease on Bone Density and Fragility Fractures: Associations and Mechanisms
Journal of Obesity & Metabolic Syndrome
2024 .06
Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study
Clinical and Molecular Hepatology
2024 .04
Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD
Clinical and Molecular Hepatology
2024 .01
Diverse Functions of Macrophages in Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease: Bridging Inflammation and Metabolism
Immune Network
2025 .02
No More NAFLD: The Term Is Now MASLD
Endocrinology and Metabolism
2024 .02
The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective
Clinical and Molecular Hepatology
2024 .04
Correspondence on Editorial regarding “Identification of signature gene set as highly accurate determination of MASLD progression”
Clinical and Molecular Hepatology
2024 .04
Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD
Clinical and Molecular Hepatology
2024 .04
WFDC2 exacerbates metabolic dysfunction associated steatotic liver disease
한국실험동물학회 학술발표대회 논문집
2025 .02
Ursolic acid in health and disease
The Korean Journal of Physiology & Pharmacology
2018 .05
Three-Step Algorithm for Screening High-Risk Group of Metabolic Dysfunction-Associated Steatotic Liver Disease in General Population
Gut and Liver
2024 .03
Nighttime limited fiber supplementation ameliorates metabolic dysfunction-associated fatty liver disease in mice via gut microbiota modulation
한국실험동물학회 학술발표대회 논문집
2025 .02
Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Clinical and Molecular Hepatology
2024 .07
Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
Diabetes and Metabolism Journal
2024 .03
0